AstraZeneca PLC
AstraZeneca PLC is a biopharmaceutical company that develops and commercializes prescription medicines. Its marketed products include treatments for cardiovascular, renal, metabolism, oncology, and rare diseases. The company serves physicians through distributors and local offices worldwide. It has partnerships with Neurimmune AG and BenevolentAI to develop new treatments. Founded in 1992, the company is headquartered in Cambridge, UK.
Overview
Strengths
- Creates economic value: ROIC of 19.2% against a cost of capital (WACC) of 5.6%, a spread of 13.5 percentage points.
- High-quality earnings: over the last 6 years, free cash flow added up to 120% of reported net income.
- Consistent growth: revenue has compounded at 17.2% a year over 5 years, rising every year.
- Earnings are projected to grow at a solid rate (11.7% per year).
- Paying down debt: long-term debt fell by 3.8 percentage points of total assets last year.
Weaknesses
- Our discounted cash flow target price (945.69 SEK) is 49% below the current price.
- Unstable profitability: operating margin ranged from 0% to 23% over the last 6 years, with operating losses in 1 of them.
- Valued at a premium to its Drug Manufacturers - General peers: P/FCF 33.2x vs. a median of 20.8x.
Key Financial Data